Skip to main content
BB Biotech AG logo

BB Biotech AG — Investor Relations & Filings

Ticker · BION ISIN · CH0027659793 LEI · 391200MBZQNPFHIVKO34 SW Financial and insurance activities
Open in API
Filings indexed 267 across all filing types
Latest filing 2026-04-24 Report Publication Anno…
Country CH Switzerland
Listing SW BION

About BB Biotech AG

https://www.bbbiotech.ch/en/bb-biotech

BB Biotech AG is an investment company specializing in the fast-growing biotechnology market. With over 30 years of experience, it is one of the world's largest investors in this sector. The company's investment strategy focuses on a portfolio of publicly listed companies that are developing and commercializing novel drugs. These target companies are selected for their potential to create significant value for the healthcare system by addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
BB Biotech AG publishes its interim report
Report Publication Announcement Classification · 91% confidence The document is an ad-hoc announcement under Art. 53 LR stating that BB Biotech AG has published its interim report as at March 31, 2026 and provides a link to the full report. The interim report itself is not included; only its publication is announced. This fits the definition of a Report Publication Announcement (RPA).
2026-04-24 English
EQS-Adhoc: BB Biotech AG publishes its interim report
Report Publication Announcement Classification · 90% confidence The document is a short ad hoc regulatory announcement (Art. 53 LR) of BB Biotech AG stating that its interim report as of March 31, 2026 has been published and provides a link to download it. It does not contain the full interim report itself, but merely announces its publication. Under the “menu vs. meal” rule, such a brief notice is categorized as a Report Publication Announcement (RPA).
2026-04-24 English
EQS-Adhoc: BB Biotech AG veröffentlicht Zwischenbericht
Report Publication Announcement Classification · 85% confidence The document is an ad-hoc news release (Art. 53 KR) under 5,000 characters that summarizes Q1 results and states that the interim report as of March 31, 2026 is now published and available on the website. It does not contain the full interim financial report itself, but serves to announce its publication. According to the “menu vs meal” rule and definitions, this is a Report Publication Announcement (RPA).
2026-04-24 German
EQS-News: BB Biotech Q1 2026: Share price outperformance, narrowing discount and active portfolio repositioning
Report Publication Announcement Classification · 95% confidence The document is a media release titled 'BB Biotech Q1 2026' which provides a summary of financial performance, portfolio changes, and strategic outlook for the first quarter. While it contains substantive financial data and analysis, the final paragraph explicitly states: 'The interim report as at March 31, 2026, is available under [link]'. This indicates that the current document is a press release announcing the publication of the actual interim report, rather than the report itself. According to the 'MENU VS MEAL' rule, this is classified as a Report Publication Announcement (RPA). Q1 2026
2026-04-24 English
EQS-News: BB Biotech Q1 2026: Outperformance Aktienkurs, Reduktion des Abschlags und aktive Neupositionierung
Interim / Quarterly Report Classification · 95% confidence The document is a quarterly update (Q1 2026) for BB Biotech AG. It contains detailed financial performance metrics, including share price returns, NAV changes, net loss figures, and a breakdown of portfolio changes. While it mentions that the full interim report is available via a link at the end, the document itself provides substantive financial data, performance analysis, and management commentary, which qualifies it as an Interim/Quarterly Report (IR) rather than a mere publication announcement. Q1 2026
2026-04-24 German
Q1 statement / Q1 financial report 2026
Interim / Quarterly Report Classification · 100% confidence The document is titled 'BB Biotech Interim Report Q1 2026' and contains comprehensive financial data, including consolidated interim financial statements, performance comparisons, and a shareholder letter. It is a full quarterly report, not an announcement or a summary, and it contains substantive financial data, fitting the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-04-24 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.